Genmab AS (LTS:0MGB) Change In Receivables : kr-947 Mil (TTM As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Genmab AS Change In Receivables?

Genmab AS's change in receivables for the quarter that ended in Mar. 2025 was kr856 Mil. It means Genmab AS's Accounts Receivable declined by kr856 Mil from Dec. 2024 to Mar. 2025 .

Genmab AS's change in receivables for the fiscal year that ended in Dec. 2024 was kr-1,580 Mil. It means Genmab AS's Accounts Receivable increased by kr1,580 Mil from Dec. 2023 to Dec. 2024 .

Genmab AS's Accounts Receivable for the quarter that ended in Mar. 2025 was kr5,513 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Genmab AS's Days Sales Outstanding for the three months ended in Mar. 2025 was 101.97.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Genmab AS's liquidation value for the three months ended in Mar. 2025 was kr17,533 Mil.

Genmab AS Change In Receivables Historical Data

The historical data trend for Genmab AS's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Change In Receivables Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

309.30

-1,010.88

-2,145.92

808.78

-1,579.91

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															267.53	-1,314.51	-330.68	-156.84	855.51

Genmab AS Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-947 Mil.

Genmab AS (LTS:0MGB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Genmab AS's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5512.541	/	4933	*	91
=	101.97

2. In Ben Graham's calculation of liquidation value, Genmab AS's accounts receivable are only considered to be worth 75% of book value:

Genmab AS's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	22257.142	-	8900.097	+	0.75 * 5512.541	+	0.5 * 82.792
=	17,533

Genmab AS Change In Receivables Related Terms

Thank you for viewing the detailed overview of Genmab AS's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines